Stereotactic body radiotherapy in patients with bone oligometastases from breast cancer: results from a European multicenter cohort study
Background and purpose - The interdisciplinary treatment concept for bone metastases (BoM) of oligometastatic breast cancer includes metastasis-directed radiotherapy. We evaluated oncological outcomes of BoM treated with stereotactic body radiotherapy (SBRT) in a large European cohort. - Material an...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
May 2026
|
| In: |
Clinical and translational radiation oncology
Year: 2026, Volume: 58, Pages: 1-9 |
| ISSN: | 2405-6308 |
| DOI: | 10.1016/j.ctro.2026.101142 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ctro.2026.101142 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2405630826000376 
|
| Author Notes: | Sebastian Schäfer, Isabell Seiler, Lena Kästner, Johannes Meents, Marek Slavik, Petr Burkon, Mauro Loi, Pierluigi Bonomo, Camilla von Wachter, Panagiotis Balermpas, Anna Sabrina Schunn, Sophia Drabke, Richard Holy, Kenneth Klischies, Olaf Wittenstein, Jochen Willner, Andrea Baehr, Priska Bank, Richard Partl, Thomas Mader, Bernd Frerker, Fabian Lohaus, Felix Ehret, Maike Trommer, Eleni Gkika, Alexander Rühle, Matthias Guckenberger, Christos Moustakis, Thomas Brunner, Oliver Blanck, Judit Boda- Heggemann, Nils H. Nicolay, Franziska Nägler |
| Summary: | Background and purpose - The interdisciplinary treatment concept for bone metastases (BoM) of oligometastatic breast cancer includes metastasis-directed radiotherapy. We evaluated oncological outcomes of BoM treated with stereotactic body radiotherapy (SBRT) in a large European cohort. - Material and methods - Data of breast cancer patients treated with SBRT for BoM between 2010 and 2024 at 17 European cancer centers were retrospectively collected. Treatment and dose concepts were analyzed regarding their impact on freedom from local recurrence (FFLR), overall survival (OS), progression-free survival (PFS), and safety profile. - Results - With a median follow-up of 29.6 months (interquartile range: 15.0-48.0), 109 patients with 147 BoM were analyzed. SBRT was performed with a prescribed dose of median 35 Gy in median 5 fractions. 1-/3-year FFLR for mean biologically effective dose (BED10) ≥ 50 Gy in the gross tumor volume (GTVmean) was 98.1% (95%-CI: 92.7%-99.5%) and 93.9% (95%-CI: 85.5%-97.5%), respectively. For GTVmean BED10 ≥ 50 Gy, 1-/3-year PFS was 62.1% (95%-CI: 43.6%-76.0%)/26.7% (95%-CI: 11.0%-45.4%) for non-spine BoM and 66.2% (95%-CI: 50.8%-77.8%)/35.8% (95%-CI: 21.3%-50.4%) for spine BoM. In multivariable analysis, systemic therapy (HR [hazard ratio] 0.22; p < 0.001) was associated with improved OS, while higher GTVmean BED10 (HR 0.96; p < 0.001) was associated with improved PFS and spine localization with worse PFS (HR 1.81; p = 0.02). Adverse events were rare, with fracture rates of 2.7%. - Conclusion - In this multicenter retrospective cohort analysis, SBRT of BoM from breast cancer was a well-tolerated, effective treatment. Prospective studies are needed to investigate these findings further and determine the role of standardized SBRT concepts in the multidisciplinary management of oligometastatic breast cancer. |
|---|---|
| Item Description: | Online veröffentlicht: 3. März 2026, Artikelversion: 6. März 2026 Gesehen am 30.03.2026 |
| Physical Description: | Online Resource |
| ISSN: | 2405-6308 |
| DOI: | 10.1016/j.ctro.2026.101142 |